News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ImmunoGen, Inc.
< Previous
1
2
Next >
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
February 22, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
February 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
January 04, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
December 28, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
December 10, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
December 09, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
November 21, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
November 04, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Departure of Chief Commercial Officer
November 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
October 28, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS
September 29, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
September 14, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
September 11, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
August 31, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
July 29, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO
May 26, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
May 25, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
May 10, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
May 06, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.